Deterioration in Asthma Control When Subjects Receiving Fluticasone Propionate/Salmeterol 100/50 mcg Diskus are “Stepped-Down”
Authors:
- Steven M. KoenigSKSteven M. Koenig
- Nancy OstromNONancy Ostrom
- David PearlmanDPDavid Pearlman
- Kelli Waitkus-EdwardsKWKelli Waitkus-Edwards
- Steven YanceySYSteven Yancey
- Barbara A. PrillamanBPBarbara A. Prillaman
- Paul DorinskyPDPaul Dorinsky
- 1 January 2008
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma
- Vol. 45 (8) , 681-687
Abstract
In this study, 647 subjects stable on fluticasone propionate/salmeterol Diskus 100/50 mcg BID (FSC) were randomized to continue FSC 100/50 mcg BID or "step down" to either fluticasone propionate (FP) 100 mcg BID, salmeterol (SAL) 50 mcg BID, or montelukast (MON) 10 mg once daily for 16 weeks. Overall asthma control significantly improved in the FSC group; whereas, "stepping down" to FP, SAL, or MON resulted in deterioration in asthma control, as determined by decreased measures of lung function and clinical features. This study provides support that treatment of both inflammation and smooth muscle dysfunction may be necessary to achieve and maintain asthma control in patients uncontrolled on ICS.Keywords
This publication has 15 references indexed in Scilit:
- Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapiesJournal of Allergy and Clinical Immunology, 2004
- Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice dailyJournal of Allergy and Clinical Immunology, 2003
- Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: An analysis of asthma exacerbationsJournal of Allergy and Clinical Immunology, 2001
- Combined Salmeterol 50 μ g and Fluticasone Propionate 250 μ g in the Diskus Device for the Treatment of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Salmeterol/fluticasone propionate (50500 μg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthmaRespiratory Medicine, 1999
- Asthma control during long term treatment with regular inhaled salbutamol and salmeterolThorax, 1998
- Potential Masking Effects of Salmeterol on Airway Inflammation in AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Salmeterol/Fluticasone Combination InhalerClinical Drug Investigation, 1998
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaNew England Journal of Medicine, 1997
- Statement on Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease (COPD) and AsthmaAmerican Review of Respiratory Disease, 1987